Antibodies are powerful tools in modern medicine, but securing patents for them has become increasingly complex. Following the Amgen v. Sanofi decision, companies must now provide much more detailed data to prove that their antibody inventions are fully “enabled,” making it harder to claim broad protections. While this raises the bar for innovation, it also sparks debate: does it safeguard public interest or hinder progress?